Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.95) for the year, up from their previous forecast of ($1.02). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.70) EPS.

Armata Pharmaceuticals Stock Performance

ARMP stock opened at $2.41 on Monday. The firm has a market capitalization of $87.19 million, a PE ratio of -1.47 and a beta of 0.80. Armata Pharmaceuticals has a twelve month low of $1.93 and a twelve month high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.